{"id":2236,"date":"2026-06-10T05:00:00","date_gmt":"2026-06-10T08:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2236"},"modified":"2026-06-10T05:00:00","modified_gmt":"2026-06-10T08:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-tireoide-papilifero-folicular-medular-men-2-anaplasico-tt-i-131","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-tireoide-papilifero-folicular-medular-men-2-anaplasico-tt-i-131\/","title":{"rendered":"PGRSS tireoide: papilif, medular, anaplas, TT"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica tireoide que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica tireoide<\/strong> + papil\u00edfero PTC mais comum 80% bom progn\u00f3stico<\/strong> + folicular FTC 10-15%<\/strong> + medular MTC RET MEN-2 5%<\/strong> + anapl\u00e1sico ATC <5% letal<\/strong> + lobectomia + tireoidectomia total TT + esvaziamento cervical central VI + lateral II-V<\/strong> + I-131 abla\u00e7\u00e3o iodoterapia + Lu-177 + lenvatinib + cabozantinib + selpercatinib<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (PTC + FTC + MTC + ATC + H\u00fcrthle cell + linfoma tireoide raro) + Grupo A4 (esvaziamento cervical central VI + lateral II-V + mediastino superior) + Grupo C (I-131 iodoterapia abla\u00e7\u00e3o + Lu-177 PRRT MTC + Tc-99m cintilografia + Ga-68 DOTATATE) + Grupo E (perfuro bi\u00f3psia FNAC fine needle aspiration cytology + agulha core) + Lista C5 (lenvatinib Lenvima Eisai + cabozantinib Cometriq Exelixis MTC + selpercatinib Retevmo Lilly RET-mutado + pralsetinib Gavreto Blueprint + dabrafenib+trametinib Tafinlar+Mekinist BRAF-V600E ATC + larotrectinib Vitrakvi NTRK + sorafenib Nexavar+vandetanib Caprelsa MTC). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + I-131 CNEN<\/strong> + subdimensionam targeted RET\/BRAF\/NTRK<\/strong> + perdem rastreabilidade tumor tireoide<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS tireoide opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (PTC 80% + FTC 10-15% + MTC 5% + ATC <5% + H\u00fcrthle), A4 (esvaziamento cervical central VI + lateral II-V + mediastino superior), C (I-131 abla\u00e7\u00e3o 30-200 mCi + Lu-177 PRRT MTC + Ga-68 DOTATATE + Tc-99m), E (FNAC + core + IHC + Bethesda I-VI), Lista C5 (lenvatinib SELECT + cabozantinib EXAM\/COSMIC-311 + selpercatinib LIBRETTO-001 + dabrafenib+trametinib BRF117019 ATC + larotrectinib NTRK).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica tireoide, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos tireoide<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS tireoide tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 PTC+FTC+MTC+ATC<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nBethesda I-VI+CID C73<\/td>\n<\/tr>\n
A4 cervical central+lateral<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nVI+II-V+mediast<\/td>\n<\/tr>\n
C I-131+Lu-177+Ga-68<\/td>\n1-3 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\n30-200 mCi+CNEN<\/td>\n<\/tr>\n
E FNAC+core+IHC<\/td>\n0,4-1,2 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCromogranina+TTF1<\/td>\n<\/tr>\n
Lista C5 targeted<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLenva+cabo+selper<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,9-32,7 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica tireoide m\u00e9dia porte.<\/p>\n

A1 PTC + FTC + MTC + ATC: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS tireoide \u00e9 A1. Padr\u00e3o setorial inclui (a) PTC papillary thyroid carcinoma 80%<\/strong> com bom progn\u00f3stico + cl\u00e1ssico + folicular variante + tall cell + cribriforme-morular + Warthin-like + BRAF V600E 60% + RET\/PTC fusion 20%; (b) FTC follicular thyroid carcinoma 10-15%<\/strong> com m\u00ednima invas\u00e3o + amplamente invasiva + c\u00e1psula + vascular + H\u00fcrthle cell oncoc\u00edtico + RAS muta\u00e7\u00e3o + PAX8\/PPAR\u03b3; (c) MTC medullary thyroid carcinoma 5%<\/strong> com c\u00e9lulas C parafoliculares + espor\u00e1dico 75% + heredit\u00e1rio 25% MEN-2A Sipple+MEN-2B+FMTC + RET germinativo + calcitonina + CEA + Ga-68 DOTATATE PET; (d) ATC anaplastic thyroid carcinoma <5%<\/strong> com letal sobrevida 6m + indiferenciado + dediferencia\u00e7\u00e3o PTC\/FTC + BRAF V600E 30-40% + dabrafenib+trametinib breakthrough; (e) Bethesda System for Reporting Thyroid Cytopathology<\/strong> I n\u00e3o-diagn\u00f3stico + II benigno + III AUS\/FLUS + IV neoplasia folicular + V suspeito malignidade + VI maligno + estadiamento TNM 8\u00aa edi\u00e7\u00e3o.<\/p>\n

Cl\u00ednica com A1 tireoide madura garante margem R0<\/strong> + previne recidiva cervical<\/strong> + otimiza Bethesda+TNM<\/strong>. Como discutimos no post sobre adrenal<\/a>, A1 end\u00f3crino \u00e9 base.<\/p>\n

A4 lobectomia + tireoidectomia total TT + esvaziamento cervical: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) lobectomia tireoide<\/strong> com hemitireoidectomia + istmectomia + lobectomia direita+esquerda + indica\u00e7\u00e3o PTC <4cm low-risk + diferencia\u00e7\u00e3o PTC unifocal; (b) tireoidectomia total TT<\/strong> com remo\u00e7\u00e3o completa tireoide + preserva\u00e7\u00e3o paratireoides 2-4 + identifica\u00e7\u00e3o nervo lar\u00edngeo recorrente NLR + nervo lar\u00edngeo superior NLS Cernea + indica\u00e7\u00e3o PTC>4cm\/multifocal\/bilateral\/extratireoidiana\/MTC\/ATC; (c) esvaziamento cervical central VI<\/strong> com pr\u00e9-traqueal Delphian + paratraqueal direito + esquerdo + recorrencial + 6-12 LN dissecados + indica\u00e7\u00e3o MTC rotina+PTC clinicamente positivo cN1; (d) esvaziamento cervical lateral II-V<\/strong> com jugular superior II + m\u00e9dio III + inferior IV + posterior V + indica\u00e7\u00e3o MTC + PTC LN clinicamente positivo + ipsilateral + bilateral; (e) complica\u00e7\u00e3o cir\u00fargica<\/strong> hipoparatireoidismo permanente 2-5% + les\u00e3o NLR unilateral 1-3% + bilateral <0.5% + hematoma cervical + traqueostomia emerg\u00eancia.<\/p>\n

Cl\u00ednica com A4 lobectomia+TT+esvaziamento madura escala R0<\/strong> + preserva paratireoides+NLR<\/strong> + previne hipocalcemia+disfonia<\/strong>. Conex\u00e3o com hospital especializado<\/a>.<\/p>\n

I-131 abla\u00e7\u00e3o + Lu-177 + lenvatinib + cabozantinib + selpercatinib + dabrafenib+trametinib: o est\u00e1gio iodoterapia+targeted<\/h2>\n

A terceira camada \u00e9 I-131+targeted. Padr\u00e3o setorial inclui (a) I-131 iodoterapia abla\u00e7\u00e3o remnant<\/strong> com PTC+FTC p\u00f3s-TT + 30-200 mCi VO + suspens\u00e3o T4 levotiroxina 4-6 semanas TSH>30 + dieta low-iodine 2 semanas + isolamento interna\u00e7\u00e3o 24-72h CNEN-NN-3.05; (b) rhTSH Thyrogen Genzyme<\/strong> alternativa suspens\u00e3o T4 + 0,9mg IM \u00d7 2 doses + reduz hipotiroidismo sintom\u00e1tico + dose I-131 100mCi t\u00edpica; (c) PTC\/FTC RAI-refrat\u00e1rio 1L<\/strong> lenvatinib Lenvima Eisai SELECT 24mg PO QD + sorafenib Nexavar DECISION 400mg PO BID + cabozantinib Cometriq EXAM 60-140mg PO QD MTC; (d) MTC RET-mutado\/fusion<\/strong> selpercatinib Retevmo Lilly LIBRETTO-001 160mg BID + pralsetinib Gavreto Blueprint ARROW 400mg QD + cabozantinib EXAM + vandetanib Caprelsa AstraZeneca ZETA 300mg QD; (e) ATC BRAF V600E<\/strong> dabrafenib Tafinlar+trametinib Mekinist Novartis BRF117019 + 30-50% ATC + larotrectinib Vitrakvi\/entrectinib Rozlytrek NTRK fusion + Lu-177 DOTATATE PRRT MTC + Lista C5 targeted.<\/p>\n

Cl\u00ednica com I-131+targeted madura escala remiss\u00e3o p\u00f3s-I-131 70-90%<\/strong> + escala lenvatinib SELECT PFS 18,3m<\/strong> + escala selpercatinib LIBRETTO-001 ORR 73%<\/strong>. Conex\u00e3o com I-131 brachy<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade tireoide<\/h2>\n

Cl\u00ednica tireoide s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 8.000-24.000<\/strong> mas perda de A4+I-131+targeted.<\/p>\n

Cl\u00ednica tireoide A1 + A4 + I-131.<\/strong> 3 fluxos. Custo mensal R$ 20.000-50.000<\/strong>, captura cirurgia + iodoterapia.<\/p>\n

Cl\u00ednica tireoide 5 fluxos completos.<\/strong> A1+A4+I-131+E+targeted + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 38.000-90.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa tireoide + lenvatinib+selpercatinib targeted.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica tireoide<\/h2>\n

O primeiro \u00e9 a subdimensionamento I-131 CNEN-NN-3.05<\/strong>. Sem isolamento interna\u00e7\u00e3o 24-72h + decaimento dep\u00f3sito + IPEN\/CNEN = n\u00e3o-conformidade radioativa + risco multa interdi\u00e7\u00e3o + zero prote\u00e7\u00e3o radiol\u00f3gica profissional+familiar.<\/p>\n

O segundo \u00e9 a mistura A1 PTC+FTC+MTC+ATC<\/strong>. Confunde rastreabilidade tumor + impossibilita Bethesda+TNM + risco indica\u00e7\u00e3o targeted inadequada (ATC vs MTC vs PTC).<\/p>\n

O terceiro \u00e9 a falta de protocolo paratireoide preserva\u00e7\u00e3o + NLR identifica\u00e7\u00e3o<\/strong>. Sem rastreabilidade ICG fluoresc\u00eancia + IONM intraoperative neuromonitoring NIM Medtronic+Inomed = risco hipocalcemia permanente 2-5% + disfonia bilateral risco traqueostomia emerg\u00eancia.<\/p>\n

A regula\u00e7\u00e3o de PGRSS tireoide no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBEM Sociedade Brasileira Endocrinologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS tireoide 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 PTC papil\u00edfero 80% BRAF V600E+RET\/PTC fusion+folicular variante+tall cell+FTC folicular 10-15% m\u00ednima invas\u00e3o+amplamente invasiva+H\u00fcrthle oncoc\u00edtico+MTC medular 5% MEN-2A Sipple+MEN-2B+FMTC+RET germinativo+calcitonina+CEA+ATC anapl\u00e1sico <5% letal+BRAF V600E+Bethesda I-VI+CID C73+TNM 8\u00aa, A4 lobectomia hemi+TT total+paratireoides preserva\u00e7\u00e3o+NLR identifica\u00e7\u00e3o ICG+NIM Medtronic+esvaziamento central VI 6-12 LN+lateral II-V+hipoparatireoidismo 2-5%, C I-131 abla\u00e7\u00e3o 30-200 mCi+suspens\u00e3o T4+TSH>30+dieta low-iodine+rhTSH Thyrogen Genzyme+CNEN-NN-3.05+isolamento 24-72h+IPEN+Lu-177 PRRT MTC+Ga-68 DOTATATE+Tc-99m, E FNAC fine needle aspiration cytology+core+IHC TTF1+thyroglobulin+calcitonin, Lista C5 lenvatinib Lenvima Eisai SELECT PFS 18,3m+sorafenib Nexavar DECISION+cabozantinib Cometriq Exelixis EXAM\/COSMIC-311+selpercatinib Retevmo Lilly LIBRETTO-001 ORR 73%+pralsetinib Gavreto Blueprint ARROW+vandetanib Caprelsa AstraZeneca ZETA+dabrafenib Tafinlar+trametinib Mekinist Novartis BRF117019 ATC+larotrectinib Vitrakvi+entrectinib Rozlytrek NTRK.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia tireoide: papil\u00edf + medular + anapl\u00e1s + TT + I-131. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,1954,1951,3070],"class_list":["post-2236","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-i-131","tag-tireoide","tag-tt"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2236"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2236\/revisions"}],"predecessor-version":[{"id":4341,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2236\/revisions\/4341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2235"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}